Study Finds Serotonin Plays a Role in Development of Mammary Glands
The development of mammary glands is controlled primarily by endocrine hormones. A study led by Nelson Horseman, PhD, professor and interim chair of the Department of Molecular and Cellular Physiology at the
, shows that serotonin (a brain neurotransmitter) also plays a role in mammary gland development. Findings from this study appear in the Feb. 10 issue of
Developmental Cell
in an article titled "Serotonin Regulates Mammary Gland Development via an Autocrine Paracrine Loop."
"It was a complete surprise when we found that serotonin, a chemical best known for its involvement in mood regulation, plays an important role in controlling the secretion of milk in the mammary glands," said Dr. Horseman.
Serotonin, along with other regulatory hormones such as dopamine and adrenaline, is classified as a biogenic monoamine. Until now, this molecule has not been associated with the development of mammary glands. Dr. Horseman's group found that mammary glands stimulated by prolactin express genes necessary for the biosynthesis of serotonin.
Findings from this study may suggest that drugs that alter serotonin synthesis or activity could have effects on milk production, milk quality, or breast cancer.
Co-authors from UC include: Manabu Matsuda, PhD, former postdoctoral fellow; Tatsuhiko Imaoka, PhD, former graduate student; Archie J. Vomachka, PhD, visiting professor from Arcadia University in Pennsylvania; Gary A. Gudelsky, PhD, professor in the UC College of Pharmacy; Zhaoyuan Hou, PhD, former graduate student; Meenakshi Mistry, research associate in the Department of Molecular and Cellular Physiology; Jason P. Bailey, graduate student in the Department of Molecular and Cellular Physiology; and Kathryn M. Nieport, research assistant in the Department of Molecular and Cellular Physiology.
View the entire article online at
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.